Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30753324 | 0.91 | KDM4E (0.37) | KDM4ECYP1A2CYP2D6CYP2C9MAPK1 | |
| SCHEMBL10468498 | 0.88 | ALDH1A1 (0.38) | KDM4ECYP1A2CYP2D6CYP2C9MAPK1 | |
| SCHEMBL10468840 | 0.87 | ALDH1A1 (0.40) | KDM4ECYP1A2CYP2D6CYP2C9MAPK1 | |
| SCHEMBL9337728 | 0.87 | ALDH1A1 (0.40) | KDM4ECYP1A2CYP2D6CYP2C9MAPK1 | |
| SCHEMBL25232302 | 0.85 | CYP2D6 (0.36) | KDM4ECYP1A2CYP2D6CYP2C9MAPK1 | |
| SCHEMBL24021029 | 0.84 | KDM4E (0.34) | KDM4ECYP1A2CYP2D6CYP2C9MAPK1 | |
| SCHEMBL1441645 | 0.84 | KDM4E (0.34) | KDM4ECYP1A2CYP2D6CYP2C9MAPK1 | |
| SCHEMBL17811563 | 0.84 | BACE1 (0.39) | KDM4ECYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL1440620 | 0.81 | TSHR (0.35) | KDM4EL3MBTL1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL12820211 | 0.80 | KDM4E (0.36) | KDM4ECYP1A2CYP2D6CYP2C9MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9814699-B2 | Chemical compounds | Janssen Pharmaceuticals, Inc. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9814699-B2 | Chemical compounds | Janssen Pharmaceuticals, Inc. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9814699-B2 | Chemical compounds | Janssen Pharmaceuticals, Inc. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20160158201-A1 | CHEMICAL COMPOUNDS | JANSSEN PHARMACEUTICALS INC (US) | 2016-06-09 | — | — | US | disclosed |
| US-20160158201-A1 | CHEMICAL COMPOUNDS | JANSSEN PHARMACEUTICALS INC (US) | 2016-06-09 | — | — | US | disclosed |
| US-20160158201-A1 | CHEMICAL COMPOUNDS | JANSSEN PHARMACEUTICALS INC (US) | 2016-06-09 | — | — | US | disclosed |
| EP-3006441-A1 | NS5A INHIBITORS | Janssen Pharmaceuticals, Inc. (US) | 2016-04-13 | — | — | EP | disclosed |
| EP-3006441-A1 | NS5A INHIBITORS | Janssen Pharmaceuticals, Inc. (US) | 2016-04-13 | — | — | EP | disclosed |
| US-20150374668-A1 | CHEMICAL COMPOUNDS | JANSSEN PHARMACEUTICALS INC (US) | 2015-12-31 | — | — | US | disclosed |
| US-20150374668-A1 | CHEMICAL COMPOUNDS | JANSSEN PHARMACEUTICALS INC (US) | 2015-12-31 | — | — | US | disclosed |
| US-20130072690-A1 | Chemical Compounds | GLAXOSMITHKLINE LLC (US) | 2013-03-21 | — | — | US | disclosed |
| US-8344155-B2 | Chemical compounds | GLAXOSMITH KLINE LLC (US) | 2013-01-01 | — | — | US | disclosed |
| US-8344155-B2 | Chemical compounds | GLAXOSMITH KLINE LLC (US) | 2013-01-01 | — | — | US | disclosed |
| US-8344155-B2 | Chemical compounds | GLAXOSMITH KLINE LLC (US) | 2013-01-01 | — | — | US | disclosed |
| EP-2473056-A1 | CHEMICAL COMPOUNDS | GlaxoSmithKline LLC (US) | 2012-07-11 | — | — | EP | disclosed |
| US-20110152237-A1 | Chemical Compounds | GLAXOSMITHKLINE LLC | 2011-06-23 | — | — | US | disclosed |
| US-20110152237-A1 | Chemical Compounds | GLAXOSMITHKLINE LLC | 2011-06-23 | — | — | US | disclosed |
| US-20110152237-A1 | Chemical Compounds | GLAXOSMITHKLINE LLC | 2011-06-23 | — | — | US | disclosed |
| WO-2011028596-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-03-10 | — | — | WO | disclosed |
| WO-2011028596-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150374668-A1 | CHEMICAL COMPOUNDS | SLC10A1, UGT1A3, UGT2B7 | KDM4E 4538/4885L3MBTL1 4696/4885CYP1A2 61/4885 |
| US-20160158201-A1 | CHEMICAL COMPOUNDS | SLC10A1, UGT1A3, UGT2B7 | KDM4E 4538/4885L3MBTL1 4696/4885CYP1A2 61/4885 |
| US-20130072690-A1 | Chemical Compounds | SLC10A1, UGT1A3, UGT2B7 | KDM4E 4538/4885L3MBTL1 4696/4885CYP1A2 61/4885 |
| US-20110152237-A1 | Chemical Compounds | SLC10A1, UGT1A3, UGT2B7 | KDM4E 4538/4885L3MBTL1 4696/4885CYP1A2 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.